FDA approves first liquid biopsy test that uses advanced gene sequencing
Bio Pharma Dive
AUGUST 10, 2020
The test, developed by Guardant Health, combines next-generation sequencing with a cancer blood test.
246 
Illumina debuts its multi-gene test for cancer in Europe
pharmaphorum
MARCH 15, 2022
Gene sequencing specialist Illumina has started rolling out a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treatment for a broad range of cancers. The company is preparing to file for FDA approval of TruSight Oncology in the US later this year.
UK cancer mutation testing firm Biofidelity raises $12m
pharmaphorum
AUGUST 21, 2020
Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing. This type of testing is usually carried out on lung tissue biopsies, which is an invasive and expensive procedure with a 10% failure rate.
Let's personalize your content